Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.

about

Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.

Item

http://www.wikidata.org/entity/Q47344786

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Comparative Efficacy of Daratu ...... Adjusted Indirect Comparison.

@en

Comparative Efficacy of Daratu ...... Adjusted Indirect Comparison.

@nl

type

Item

label

Comparative Efficacy of Daratu ...... Adjusted Indirect Comparison.

@en

Comparative Efficacy of Daratu ...... Adjusted Indirect Comparison.

@nl

prefLabel

Comparative Efficacy of Daratu ...... Adjusted Indirect Comparison.

@en

Comparative Efficacy of Daratu ...... Adjusted Indirect Comparison.

@nl

P1476

Comparative Efficacy of Daratu ...... Adjusted Indirect Comparison.

@en

P2093

Andrew Belch

http://www.w3.org/2001/XMLSchema#string

Joris Diels

http://www.w3.org/2001/XMLSchema#string

Martin Vogel

http://www.w3.org/2001/XMLSchema#string

Suzy Van Sanden

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Human CD38: a (r)evolutionary story of enzymes and receptors

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Impact of pomalidomide therapy in multiple myeloma: a recent survey.

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

P304

279-287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2017-0103

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Albert Oriol

T Ito

P577

2017-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29192016

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

P932

5905688

http://www.w3.org/2001/XMLSchema#string